Glatiramer Acetate Reduces Risk of Cardiovascular Disease and Myocardial Infarction

Discussion

Our finding that GA reduces risk of cardiovascular disease and myocardial infarction confirms the results of a previous study (1, 2). GA works primarily by inducing a shift from pro-inflammatory Th1 cells to anti-inflammatory Th2 cells, thus reducing inflammation in the CNS. Additionally, GA increases the release of brain-derived neurotrophic factor (BDNF), which promotes neuronal survival and repair. While the drug’s primary action is CNS-specific, it may interact with systemic immune pathways, potentially influencing cardiovascular function.

Although most GA-treated patients tolerate the drug well, there have been sporadic reports of cardiovascular side effects (4). The most documented events include:

Transient chest pain. Occurring in about 10-15% of patients, this symptom typically lasts for a few minutes after injection and resolves without intervention. Despite its alarming nature, investigations using electrocardiograms (ECGs) and cardiac biomarkers often show no evidence of ischemia or infarction. The mechanism remains unclear, but it may be related to autonomic nervous system activation.

Palpitations and arrhythmias. There are rare cases of patients reporting palpitations or arrhythmias shortly after GA administration. These events are usually benign and self-limiting but can cause significant concern in patients, especially those with pre-existing arrhythmias or structural heart disease.

Hypotension and vasodilation. GA may induce mild hypotension and vasodilation in some patients, contributing to dizziness or lightheadedness, particularly following injection. While generally harmless, these symptoms may exacerbate cardiovascular risk in vulnerable populations.

In addition to its emerging role in cardiovascular disease, GA has been implicated in other immune-related conditions, revealing a broader spectrum of biological activity that may influence clinical risk and benefit. For example, a case study of sclerosing microcystic adenocarcinoma (SMA) identified GA use in the context of prior immunosuppressive therapy for multiple sclerosis, raising questions about potential links between long-term immunomodulation and oncogenesis (8). Although causality was not established, the observation highlights the need to carefully evaluate immune-modifying therapies in populations at risk for rare malignancies. Separately, GA has shown promise in enhancing immune cell function in cancer immunotherapy contexts. A study by Hong et al. demonstrated that adoptively transferred T cells engineered to express CCR10 – guided by tumor-derived chemokine gradients – exhibited significantly improved trafficking and anti-tumor efficacy in vivo (9). This is relevant because GA has been shown to influence chemokine receptor expression on immune cells in other settings, suggesting a plausible role in modulating immune cell trafficking beyond its established effects in neuroinflammation. Together, these findings suggest that GA’s mechanisms of action extend across immune and vascular systems, warranting further investigation into both its therapeutic potential and safety in diverse clinical contexts.

Cardiac events in high-risk populations. Case reports have described more severe cardiovascular events such as MI and congestive heart failure in patients with pre-existing cardiovascular conditions. Although these cases are exceedingly rare, they underscore the need for careful patient selection and monitoring, particularly in MS patients with multiple cardiovascular risk factors.

Multiple sclerosis affects women 4 times as often as men, though cardiovascular disease is found predominantly in men. A weakness in our analysis is that we were not able to stratify the MedWatch/OpenVigil data by sex, since the number of adverse events in both analyses (acute myocardial infarction and cardiovascular disease, Table I and Table II) was too small.

We conclude that despite rare adverse cardiovascular side effects and given its established safety profile, GA may show promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.